Document:

<PAGE>

             CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
        AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT
             HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                                                  Exhibit 10.5

                                   Task Order
                             (Task Order # [*])

When signed by the parties below, the following Task Order hereby
incorporates by reference the Agreement for Purchase and Sale of Custom
Semiconductor Products ("the Agreement"), with the agreement number of X0419,
as Task Order [*]. This Task Order is solely governed by the terms and
conditions of Agreement Number [*].

This Task Order is for a foundry program in which IBM will build untested 8"
wafers using GDS II design data supplied by IMI and as further described in
this Task Order. The parties agree that under this Task Order, IBM will
process wafer lots through front end manufacturing to "common stock" (also
known as front-end-of-the-line or FEOL processing) as "base wafers" and
perform subsequent back-end-of-the-line (or BEOL) processing for
"personalized wafers." IMI agrees to furnish detailed technical requirements
for base and personalized wafers. IBM agrees to process wafers as forecasted
and ordered by IMI per the terms of this Task Order.

1.0      TERM OF TASK ORDER: THIS TASK ORDER WILL BE EFFECTIVE ON DECEMBER 1,
1999 AND WILL EXPIRE ON NOVEMBER 30, 2001.

2.0      PRODUCT NAME AND DESCRIPTION:

              Name:  Z Chip

              Description:

                           Technology:    CMOS5SF .35um with OP/BR layer
                           Metal Levels:  3
                           Deliverables:  Untested wafers

3.0      PRODUCT SPECIFICATIONS:

              Untested wafers manufactured per Customer's GDSII tape and the IBM
              CMOS5SF process technology (Specification # [*]). Untested
              wafers will be delivered per the Wafer Acceptance Criteria in
              Exhibit A-2, attached hereto.

4.0      DELIVERABLE ITEMS:

              IMI Deliverable Items:          -- GDS II Tape in CMOS5SF ground
                                              rule format (Specification
                                              [*])

                                              -- Specific designs will be
                                              provided per forecast in
                                              Section 5 and updated
                                              monthly.

              IBM Deliverable Items:          -- CMOS 5SF Spice models

                                              -- CMOS 5SF Process Ground Rules

                                              -- Deliver Prototypes and Product
                                              per delivery schedules in
                                              Section 10

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

<PAGE>

5.0      QUARTERLY REVIEWS

The parties agree they shall meet at least once every calendar quarter during
the term of the Agreement to review the Agreement with respect to pricing,
volume commitment, applicable Products and processes, and the scope of
manufacturing. In particular, IBM and IMI agree to review yield results and
prices on a quarterly basis. The prices in Section 9.0 are based on a wafer
target defect density yield of [*]%. Actual wafer yield will be based on the
first 3-10 production lots. IBM may adjust prices based on the yield results.

6.0      PURCHASE ORDERS

In addition to the information listed in items a-d of section 3 of the
Agreement, IMI's purchase orders shall specify whether base wafers for FEOL
processing or BEOL processing for personalized wafers.

7.0      PRODUCT DEMAND FORECAST:

12 month rolling forecast.

<TABLE>
<CAPTION>

Year: 1999                          Year:   2000
<S>     <C>      <C>      <C>      <C>     <C>      <C>      <C>      <C>      <C>     <C>      <C>
Sept.    Oct.     Nov.     Dec.     Jan.    Feb.     Mar.     Apr.     May      June    July     Aug.
[*]      [*]      [*]      [*]      [*]     [*]      [*]      [*]      [*]      [*]     [*]      [*]

</TABLE>

8.0      ENGINEERING CHARGES (NRE CHARGES):

              NRE Charges include the following:

8.1      Full Mask Set (FEOL/BEOL) CMOS 5SF with 3LM and BR: $[*].

                           The Full Mask Set NRE includes
                  1.       Spice models (CMOS 5SF simulation models)
                  2.       Process Ground Rules (CMOS 5SF ES# [*], dated
                           June 1997)
                  3.       Processing Customer's GDS II tape
                  4.       Mask build
                  5.       One (1) personalization and three (3) Prototype
                           wafers. In the event that IBM is unable to deliver
                           the three (3) Prototype wafers included in the NRE
                           charge, IBM will issue IMI a credit equivalent to one
                           and one-half (1.5) times the Product unit price for
                           each Prototype wafer that IBM fails to deliver.

8.2      BEOL Personalizations (3 levels metal BEOL):

                           [*] (when Customer Delivers the GDS II tape
                           with the Customer run DRC file).

                           [*] for IBM DRC Check (applicable when IMI fails
                           to provide an IBM and IMI approved DRC, with IMI's
                           GDS II tape)

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

<PAGE>

                           Once the Customer has purchased and paid for 150
                           wafers of a personalization design, IBM will provide
                           a [*] discount on the next personalization NRE.

               The BEOL Personalizations NRE includes:

                           1. 3LM RIT B Mask Sets
                           2. One (1) personalization (design) per each BEOL
                              Personalization
                           3. Three Prototype (3) wafers

IBM shall make up to three (3) additional Prototype wafers per
personalization available at a price equal to one and one-half (1.5) times
the price for production wafers set forth in Section 9.0. Notwithstanding the
foregoing, the parties acknowledge that IBM's obligation to make such
Prototypes available is conditioned upon, the manufacturing yield of the
Prototype lot for any particular personalization.

IBM shall invoice IMI for NRE charges upon the earlier of IBM's delivery of
the Prototypes or IMI's cancellation of the NRE.

9.0      PRODUCT PRICE:

The price for FEOL wafer processing ("FEOL Processing Charge") shall be [*]
of the price listed below. The FEOL Processing Charge covers the FEOL portion
of wafer processing only.

The price for BEOL wafer processing ("BEOL Processing Charge") shall be [*]
of the price listed below. The BEOL Processing Charge covers the BEOL portion
of wafer processing only.

The price for the CMOS 5SF untested wafer with 3LM (the Product) shall be
[*] for the term of this Task Order.

Minimum Order Quantity ("MOQ") is one (1) lot of twenty-four (24) wafers
(base and personalized). For each personalization, however, IMI may place
three (3) orders with an MOQ of twelve (12) wafers (one-half lot) during the
product life of that personalization.

10.0     MANUFACTURING LEAD TIME (PURCHASE ORDER LEAD TIME):

PROTOTYPES:

In response to a purchase order for Prototypes per Section 3 of the
Agreement, IBM will acknowledge the purchase order with a shipment date based
on either the normal turn around time ("NTAT") or the rapid turn around time
("RTAT") listed below. When the purchase order for Prototypes is acknowledged
with the NTAT, the Prototype wafer price will be the Product price specified
in Section 9.0.

Provided that IMI provides IBM twelve (12) calendar days advance notice prior
to delivery of its GDS II tape, the following Purchase Order Lead Times will
apply to Prototypes:

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

<PAGE>

The RTAT Purchase Order Lead Time for the full mask set (FEOL/BEOL) is [*]
calendar days from receipt of an IBM and IMI approved DRC, with IMI's GDS II
tape by IBM.

The NTAT Purchase Order Lead Time for the full mask set (FEOL/BEOL) is [*]
calendar days from receipt of an IBM and IMI approved DRC, with IMI's GDS II
tape by IBM.

The RTAT Purchase Order Lead Time for the personalization (3LM BEOL only) is
[*] calendar days from receipt of an IBM and IMI approved DRC, with IMI's GDS
II tape by IBM.

The NTAT Purchase Order Lead Time for the personalization (3LM BEOL only) is
[*] calendar days from receipt of an IBM and IMI approved DRC, with IMI's GDS
II tape by IBM.

In the event IBM ships a RTAT Prototype more than one (1) day after the
shipment date stated in its purchase order acknowledgment, then the charge
for such Prototype will be reduced to the price for Products referenced in
Section 9.

WAFER PRODUCTION:

Production Purchase Order Lead Time for Product for the full mask set
(FEOL/BEOL) is [*] calendar days.

Production Purchase Order Lead Time for Product for personalization (3LM,
BEOL only) is [*] calendar days.

The above Product Purchase Order Lead Times assume the mask set is complete.

The parties agree to review the Production Purchase Order Lead Time on a
quarterly basis and to make any adjustments to the Production Purchase Order
Lead Time upon mutual agreement. Any such mutual agreement shall be in
writing.

11.0     ORDER CHANGES / CANCELLATION CHARGES:

In accordance with Section 6 of the Agreement, the following charges will
apply to any canceled IMI order or any portion thereof.

11.1  If any purchase order for FEOL processing is canceled after wafer
start, IMI shall pay one hundred percent (100%) of the FEOL Processing Charge.

11.2  If any purchase order for BEOL is canceled after the start of wafer
personalization, IMI shall pay one hundred percent (100%) of the BEOL
Processing Charge.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

<PAGE>

12.0     FEOL WAFER INVENTORY MANAGEMENT

Unless otherwise mutually agreed to in writing, IBM may ship FEOL processed
base wafers that have been in the base wafer finished goods inventory for one
hundred eighty (180) days or more and invoice IMI for the associated base
wafer FEOL processing charge. Receipt of payment by IBM for those invoices
will be due net thirty (30) days after the date of invoice.

13.0     PRODUCTION END-OF-LIFE NOTICE:

IBM will provide IMI with a minimum of eighteen (18) months prior written
notification ("End-of-Life Notice") if IBM plans to cease production in a
technology or wafer size form factor under this Task Order. IMI must place
any and all purchase orders for all base wafers to be discontinued within
twelve (12) months of the date IBM issued the End-of-Life Notice and for all
personalization wafers to be discontinued within fifteen (15) months of the
date IBM issues the End-of-Life Notice. IMI must take delivery of all such
discontinued Product within eighteen (18) months of the date IBM issued the
End-of-Life Notice.

14.0     RMA PROCEDURES FOR WARRANTY RETURNS

The revision of IBM Microelectronics Division's return material authorization
("RMA") procedures applicable at the time IMI returns Product under a
warranty claim shall apply. The current revision of the RMA procedures are
attached hereto for reference as Exhibit B.

15.0   TASK ORDER TECHNICAL COORDINATORS:

       IBM Microelectronics                     IMI
       281 Winter Street                        525 Los Coches Street
       Waltham, MA  02154                       Milpitas, California  95054

       FAX:  (781)-642-5909                     FAX:  (408)-263-6571
       Attn:  Donna Hohman                      Attn:  Arvinder Chadha

16.0   SHIPPING/BILLING/ORDERING LOCATIONS:

       Customer's Ship to Location:             Customer's Bill to Location:

                     Per purchase orders        525 Los Coches Street
                                                Milpitas, California  95054

                                                FAX:  (408)-263-6571
                                                Attn:  Arvinder Chadha

<PAGE>

        IBM's Ordering Location:

        International Business
        Machines Corporation
        1055 Joaquin Road
        Mountain View, CA  94043

        Attention:  John R. Sepko
        Fax:  650-694-3096

17.0    WORK-IN-PROGRESS REPORTS

Once a week during the term of this Attachment, IBM will provide weekly
work-in-progress report ("WIP Report") to IMI in a form determined by IBM.

Agreed to and Accepted By:

International Business Machines                 International Microcircuits
Corporation                                     Incorporated

By:  /s/ Peter D. Hansen                        By:  /s/ Arvinder S. Chadha
   -----------------------------                   ---------------------------
   Authorized Signature                            Authorized Signature

Name:  Peter D. Hansen                          Name:  Arvinder Chadha

Title:  VP North American Sales                 Title:  VP Manufacturing

Dated:  12/13/99                                Dated:<PAGE>

                                                                   Exhibit 10.6

                        INTERNATIONAL MICROCIRCUITS, INC.

                               3,028,758 Shares of
                    Convertible Participating Preferred Stock

                         ------------------------------

                       PREFERRED STOCK PURCHASE AGREEMENT

                         ------------------------------

                             As of November 19, 1997

<PAGE>

                        INTERNATIONAL MICROCIRCUITS, INC.
                       Preferred Stock Purchase Agreement
                             as of November 19, 1997

                                      INDEX

<TABLE>
<CAPTION>
                                                                                                   Page
                                                                                                   ----
<S>          <C>                                                                                   <C>
SECTION 1.   PURCHASE AND SALE OF-PREFERRED SHARES....................................................1
    1.1      Description Securities...................................................................1
    1.2      Sale and Purchase........................................................................1
    1.3      Closing..................................................................................1

SECTION 2.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY............................................1

SECTION 3.   REPRESENTATIONS AND WARRANTIES OF THE INVESTORS..........................................2

SECTION 4.   CONDITIONS OF PURCHASE...................................................................3
    4.1      Pre-Closing Transactions.................................................................3
    4.2      Satisfaction of Conditions...............................................................4
    4.3      Opinion of Counsel.......................................................................4
    4.4      Authorization............................................................................4
    4.5      Closing of Stock Redemption..............................................................4
    4.6      Stockholders' Agreement..................................................................4
    4.7      Employment and Non-Competition Agreement.................................................4
    4.8      Confidentiality and Non-Competition Agreement............................................5
    4.9      Resignations.............................................................................5
    4.10     Election of Directors....................................................................5
    4.11     All Proceedings Satisfactory.............................................................5
    4.12     No Violation or Injunction...............................................................5
    4.13     Hart-Scott-Rodino........................................................................5
    4.14     Consents and Waivers.....................................................................5
    4.15     No Material Adverse Change...............................................................6
    4.16     Financial Markets........................................................................6

SECTION 5.   COVENANTS OF THE COMPANY.................................................................6
    5.1      Financial Stations.......................................................................6
    5.2      Budget and Operating Forecast:  Inspection...............................................6
    5.3      Board Meetings; Indemnification..........................................................7
    5.4      Conduct of Business......................................................................7
    5.5      Hart-Scott-Rodino Filings................................................................7
    5.6      Payment of Taxes, Compliance With Laws, etc..............................................7
    5.7      Insurance................................................................................7
    5.8      Key Person Insurance.....................................................................8
    5.9      Maintenance of Properties................................................................8
    5.10     Material Adverse Changes.................................................................8
    5.11     Stock Grants.............................................................................8
    5.12     Affiliated Transactions..................................................................8
    5.13     Managing Underwriter.....................................................................9

                                        i

<PAGE>

                                TABLE OF CONTENTS
                                   (continued)

                                                                                                   Page
                                                                                                   ----
    5.14     Use of Proceeds..........................................................................9
    5.15     Enforcement of Rights....................................................................9
    5.16     Distributions on, and Redemptions of, Capital Stock......................................9
    5.17     Merger, Consolidation, Sale of Assets, Acquisitions and Other Actions....................9
    5.18     No Amendments to Articles of Incorporation..............................................10
    5.19     Capital Expenditures....................................................................10
    5.20     Reincorporation.........................................................................10
    5.21     Disclosure Statement....................................................................10
    5.22     Additional Information..................................................................11

SECTION 6.   TERMINATION.............................................................................11

SECTION 7.   GENERAL.................................................................................11
    7.1      Amendments Waivers and Consents.........................................................11
    7.2      Actions or Consents of Investors........................................................12
    7.3      Indemnification From the Company:  Expenses.............................................12
    7.4      Survival of Representations; Assignability of Rights; No Third Party Beneficiaries......14
    7.5      Governing Law...........................................................................14
    7.6      Section Headings and Gender.............................................................14
    7.7      Counterparts............................................................................14
    7.8      Notices and Demands.....................................................................14
    7.9      Dispute Resolution......................................................................15
    7.10     Remedies; Severability..................................................................15
    7.11     Integration.............................................................................15

EXHIBITS

Exhibit A - List of Investors
Exhibit B - Amended and Restated Articles of Incorporation
Exhibit C - Outstanding Capital Stock
Exhibit D - Opinion of Cooley Godward LLP
Exhibit E - Form of Stockholders' Agreement
Exhibit F - Form of Employment and Non-Competition Agreement
Exhibit G - Confidentiality and Non-Competition Agreement
Exhibit H - Director Indemnification Agreement
Exhibit I - Company's 1997 Stock Option and Grant Plan and Forms of Awards

SCHEDULES

Schedule 4.9     -    Resignations
Schedule 4.14    -    Schedule of Consents and Waivers
Schedule 5.11    -    Stock Grants
Schedule 5.14    -    Use of Bank Financing Proceeds
</TABLE>

                                        ii

<PAGE>

                       PREFERRED STOCK PURCHASE AGREEMENT

         PREFERRED STOCK PURCHASE AGREEMENT made as of this 19th day of
November, 1997, by and between INTERNATIONAL MICROCIRCUITS, !NC., a
California corporation (the "Company"), and each of the investment
partnerships and individuals named in EXHIBIT A hereto (including their
assignees as provided in Section 7.4, collectively the "Investors," and each
individually an "Investor").

         SECTION 1.          PURCHASE AND SALE OF-PREFERRED SHARES.

                  1.1      DESCRIPTION SECURITIES. The Company has authorized
the issuance and sale to the Investors of 3,028,758 shares (the "Preferred
Shares") of its authorized but unissued Convertible Participating Preferred
Stock without par value per share (the "Preferred Stock"), having the rights,
preferences and other terms set forth on Exhibit B hereto (the "Preferred
Stock Terms" ` ). The Company has authorized and has reserved, and covenants
to continue to reserve, a sufficient number of shares of its Common Stock
without par value per share (the "Common Stock"), and Redeemable Preferred
Stock without par value per share (the "Redeemable Preferred Stock"), to
satisfy the rights of conversion of the holders of the Preferred Shares. Any
shares of Common Stock and Redeemable Preferred Stock or any successor class
of capital stock of the Company hereafter issued or issuable upon conversion
of the Preferred Shares are herein referred to as "Conversion Shares," and
the Preferred Shares, and the Conversion Shares are herein collectively
referred to as the "Securities."

                  1.2      SALE AND PURCHASE. Subject to the terms and
conditions herein, at the Closing (as hereinafter defined), the Company shall
issue and sell to each of the Investors, and each Investor shall purchase
from the Company, the number of Preferred Shares set forth opposite the name
of such Investor in EXHIBIT A hereto for the purchase price of $4.44 for each
Preferred Share or $13,447,685.52 in the aggregate.

                  1.3      CLOSING. A closing (the "Closing") shall take
place at the offices of Cooley Godward LLP, Palo Alto, California, together
with the closing of the transactions contemplated by the Stock Redemption
Agreement of even date (each as hereinafter defined), at 10:00 a.m. on
December 15, 1997 or at such other place, of such other time or on such
earlier or later date as the parties may agree subject to satisfaction or
waiver of all of the conditions set forth herein and therein. At the Closing,
the Company shall deliver to each Investor a certificate or certificates
representing the Preferred Shares being acquired by such Investor in such
Investor's name or in the name of its nominee, against payment of the full
purchase price therefor by or on behalf of each Investor to the Company by
wire transfer of same day available funds. The day on which the Closing
occurs is referred to herein as the "Closing Date."

         SECTION 2.          REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

         The Company hereby represents, warrants and covenants to the Investors
as of the date hereof and as of the Closing Date as follows: (a) the Company has
full corporate authority and power to enter into this Agreement; (b) this
Agreement constitutes the valid and binding obligation of the Company
enforceable against it in accordance with its terms, except as limited by (i)
applicable bankruptcy, insolvency, reorganization, moratorium or other laws of
general

<PAGE>

application affecting enforcement of creditors' rights and (ii) general
principles of equity that restrict the availability of equitable remedies
(provided, however, that the limitations described in this clause (ii) should
not prevent the practical realization of the benefits intended by this
Agreement); and (c) the execution, delivery and performance by the Company of
this Agreement: (i) does not and will not violate any laws, rules or
regulations of the United States or any state or other jurisdiction
applicable to the Company, or require the Company to obtain any approval,
consent or waiver of, or to make any filing with, any Person that has not
been obtained or made; and (ii) does not and will not result in a breach of,
constitute a default under, accelerate any obligation under or give rise to a
right of termination of any material indenture or loan or credit agreement or
any other material agreement, contract, instrument, mortgage, lien, lease,
permit, authorization, order, writ, judgment, injunction, decree,
determination or arbitration award to which the Company or any of its
subsidiaries is a party or by which the property of the Company is bound or
affected, or result in the creation or imposition of any mortgage, pledge,
lien, security interest or other charge or encumbrance on any of the assets
or properties of the Company.

         The Company hereby further represents and warrants that immediately
after the Closing, and after giving effect to each of the transactions
contemplated by (i) this Preferred Stock Purchase Agreement (hereinafter this
"Agreement"), (ii) the Stock Redemption Agreement dated as of November 19,
1997 (the "Stock Redemption Agreement"), by and between the Company, Frank
Deverse (the "Founder") and Golden Legacy, a Nevada limited partnership,
(iii) certain Option Exercise and Cancellation Agreements, each dated as of
November __, 1997, (each an "Option Cancellation Agreement") by and between
the Company and each of the holders (the "Optionholders") of options to
purchase shares of the Company's common stock pursuant to which each such
optionholder shall have elected to exercise none, some or all of the options
held by such person and pursuant to which the remaining options held by such
person shall terminate, and (iv) the Stockholders' Agreement dated as of
November __, 1997 (the "Stockholders' Agreement"), among the Company, the
Investors named therein and the other Stockholders named therein, all of the
Company's outstanding capital stock will be owned beneficially and of record
as set forth in EXHIBIT C hereto, will be free and clear of any lien,
restriction or encumbrance and, except pursuant to the terms of the
Stockholders' Agreement, there will be no outstanding options, warrants,
rights, commitments, pre-emptive rights or agreements of any kind for the
issuance and sale of, or outstanding securities convertible into, any
additional shares of any class of the Company's capital stock, except as
provided by the terms of the Preferred Shares.

         SECTION 3.          REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

         Each Investor represents that it is an "accredited investor" as such
term is defined in Rule 501 under the Securities Act of 1933, as amended (the
"Securities Act"). Each Investor represents to the Company that it is
purchasing the Securities for its own account, for investment only and not
with a view to, or any present intention of, effecting a distribution of such
securities or any part thereof except pursuant to a registration or an
available exemption under applicable law. Each such Investor acknowledges
that its respective Securities have not been registered under the Securities
Act or the securities laws of any state or other jurisdiction and cannot be
disposed of unless they are subsequently registered under the Securities Act
and any applicable state laws or an exemption from such registration is
available.

                                       2

<PAGE>

         Each of the Investors, hereby further represents, warrants and
covenants to the Company and to the Founders as follows: (a) such Investor
has full authority and power under its charter, by-laws, governing
partnership agreement or comparable document to enter into this Agreement;
(b) this Agreement constitutes the valid and binding obligation of such
Investor, except as limited by (i) applicable bankruptcy, insolvency,
reorganization, moratorium or other laws of general application affecting
enforcement of creditors' rights and (ii) general principles of equity that
restrict the availability of equitable remedies (provided, however, that the
limitations described in this clause (ii) should not prevent the practical
realization of the benefits intended by this Agreement); and (c) the
execution, delivery and performance by such Investor of this Agreement: (i)
does not and will not violate any laws, rules or regulations of the United
States or any state or other jurisdiction applicable to such Investor, or
require such Investor to obtain any approval, consent or waiver of, or to
make any filing with, any person that has not been obtained or made; and (ii)
does not and will not result in a breach of, constitute a default under,
accelerate any obligation under or give rise to a right of termination of any
indenture or loan or credit agreement or any other agreement, contract,
instrument, mortgage, lien, lease, permit, authorization, order, writ,
judgment, injunction, decree, determination or arbitration award to which
such Investor is a party or by which the property of such Investor is bound
or affected, or result in the creation or imposition of any mortgage, pledge,
lien, security interest or other charge or encumbrance on any of the assets
or properties of such Investor.

         SECTION 4.          CONDITIONS OF PURCHASE

         Each Investor's obligation to purchase and pay for its respective
Preferred Shares at the Closing- shall be subject to compliance by the
Company with its agreements herein contained and to the fulfillment to the
Investors' satisfaction on or before the Closing Date of the following
conditions:

                  4.1      PRE-CLOSING TRANSACTIONS The Company shall have
completed the following transactions on terms satisfactory to the Investors.

                  (a)      the amendment and restatement of the Company's
Articles of Incorporation;

                  (b)      all outstanding options, warrants, or other
securities exercisable for or convertible into shares of the capital stock of
the Company shall have been either (i) exercised or converted and/or (ii)
canceled pursuant to Option Exercise and Cancellation Agreements between the
Company and each of the holders of such option, warrants or other securities;

                  (c)      as a result of the option exercises referred to in
(b) above, the Optionholders shall have acquired 558,570 shares of Common
Stock and all such shares of Common Stock acquired by the Optionholders who
acquire shares of Common Stock shall be validly issued, outstanding, fully
paid and non-assessable, and each Optionholder shall have signed the
Stockholders' Agreement as a Continuing Stockholder (as defined in the
Stockholders' Agreement); and

                  (d)      the Company shall have paid all legal and
accounting fees and related expenses incurred by the Investors in connection
with the transactions contemplated by this

                                       3

<PAGE>

Agreement, the Stock Redemption Agreement, the Stockholders' Agreement and
the Bank Financing Agreement and concurrent or related transactions.

                  4.2      SATISFACTION OF CONDITIONS. The representations
and warranties of the Company contained in this Agreement and in the
Stockholders' Agreement and the representations and warranties of the Selling
Stockholder (as defined in the Stock Redemption Agreement) contained in the
Stock Redemption Agreement shall be true and correct in all material respects
on and as of the Closing Date; provided, however, that for the purpose of
determining satisfaction of this condition, no effect shall be given to any
exception in the representations and warranties relating to materiality,
Material Adverse Effect or knowledge of the Selling Stockholder in any of the
foregoing agreements; each of the conditions specified in this Section 4
shall have been satisfied or waived in writing; and on the Closing Date a
certificate to such effect executed by the Chief Executive Officer of the
Company shall be delivered to the Investors.

                  4.3      OPINION OF COUNSEL. The Investors shall have
received an opinion of Cooley Godward LLP substantially in the form attached
hereto as EXHIBIT D.

                  4.4      AUTHORIZATION. The Board of Directors and the
stockholders of the Company shall have duly adopted resolutions in form
reasonably satisfactory to the Investors and shall have taken all action
necessary for the purpose of authorizing the Company to consummate the
transactions contemplated by the Stock Redemption Agreement, the
Stockholders' Agreement, the Bank Financing Agreement and this Agreement in
accordance with the terms thereof and hereof, including without limitation
the authorization of the issuance of the Preferred Shares, the filing of an
Articles of Incorporation in the form attached hereto as with the Secretary
of State for the State of California establishing the Preferred Shares, and
the Investors shall have received a duly executed certificate of the
Secretary of the Company setting forth a copy of such resolutions and as to
such other matters as may. be requested by the Investors together with a copy
of the Articles of Incorporation certified by the Secretary of State of the
State of California.

                  4.5      CLOSING OF STOCK REDEMPTION. Concurrently with the
closing of the purchase and sale of the Preferred Shares, the Company shall
complete the redemption of an aggregate of 4,710,000 shares of Common Stock
of the Company from the Founder and Golden Legacy, L.P. in consideration of
payments aggregating $24,115,200 pursuant to the Stock Redemption Agreement
and all conditions to the closing of the Stock Redemption Agreement shall
have been satisfied and shall not have been waived by the Company.

                  4.6      STOCKHOLDERS' AGREEMENT. The Stockholders'
Agreement in the form attached hereto as EXHIBIT E shall have been executed
and delivered by the parties hereto and all other parties holding shares of
the Company's Common Stock.

                  4.7      EMPLOYMENT AND NON-COMPETITION AGREEMENT. Ilhan
Refioglu, shall have executed and delivered an Employment Agreement in the
form of EXHIBIT F hereto.

                                       4

<PAGE>

                  4.8      CONFIDENTIALITY AND NON-COMPETITION AGREEMENT. The
Founder shall have entered into a Confidentiality and Non-Competition
Agreement in the form attached hereto as EXHIBIT G.

                  4.9      RESIGNATIONS. The Founder shall have submitted his
resignation as Chief Executive Officer effective contemporaneously with the
Closing and all of the members of the Company's Board of Directors identified
on SCHEDULE 4.9 attached hereto shall have submitted their resignation as
members of the Board of Directors effective contemporaneously with the
Closing.

                  4.10     ELECTION OF DIRECTORS. Effective subsequent to the
Closing of the transactions contemplated hereby, the Company's Board of
Directors shall include Kurt R. Jaggers and Michael C. Child as designees of
the Investors pursuant to the terms of the Articles of Incorporation, each of
whom shall also be appointed to a three-person Compensation Committee of the
Company, and the Company shall have entered into Director Indemnification
Agreements with such Directors in the form attached as EXHIBIT H.

                  4.11     ALL PROCEEDINGS SATISFACTORY. All corporate and
other proceedings taken prior to or at the Closing in connection with the
transactions contemplated by this Agreement and all documents and evidences
incident thereto shall be reasonably satisfactory in form and substance to
the Investors and the issuance and sale of the Preferred Shares shall be made
in compliance with all applicable federal and state laws.

                  4.12     NO VIOLATION OR INJUNCTION. The consummation of
the transactions contemplated by this Agreement, the Stock Redemption
Agreement and the transactions contemplated hereby and thereby shall not be
in violation of any law or regulation, and shall not be subject to any
injunction, stay or restraining order.

                  4.13     HART-SCOTT-RODINO. All required filings (the "HSR
Filings") under the Hart-Scott-Rodino Anti-Trust Improvement Act of 1976, as
amended (the "HSR Act"), shall have been completed and all applicable time
limitations under such Act shall have expired without a request for further
information by the relevant federal authorities under the HSR Act, or in the
event of such a request for further information, the expiration of all
applicable time limitations under the Act shall have occurred without the
objection of such federal authorities.

                  4.14     CONSENTS AND WAIVERS. The Company and each party
to each to the Stock Redemption Agreement, the Stockholders' Agreement and
the Bank Financing Agreement shall have obtained all consents or waivers
including, without limitation, the consents and waivers identified in
SCHEDULE 4.14 hereto necessary to execute this Agreement, the Stock
Redemption Agreement, the Stockholders' Agreement and the Bank Financing
Agreement and the other agreements and documents contemplated herein, to
issue the Securities and to carry out the transactions contemplated hereby
and thereby and shall have delivered satisfactory evidence thereof to the
Investors. All governmental filings necessary to effectuate the terms of this
Agreement, the Securities, the Stock Redemption Agreement, the Stockholders'
Agreement, the Bank Financing Agreement and the other agreements and
instruments executed and delivered by the Company in connection herewith and
therewith shall have been made or taken.

                                       5

<PAGE>

                  4.15     NO MATERIAL ADVERSE CHANGE. Between June 30, 1997
and the Closing Date, there shall have been no material adverse change in the
financial condition, properties, assets, liabilities, business, operations or
prospects of the Company, whether or not in the ordinary course of business.

                  4.16     FINANCIAL MARKETS. As of the Closing Date, there
shall have not have occurred an aggregate decline of five percent (5 %) or
more in the Nasdaq composite index from the level of such index at the close
of business on the date of this Agreement.

         SECTION 5.          COVENANTS OF THE COMPANY

         From and after the Closing the Company (which term shall be deemed
to include, for purposes of this Section 5, any subsidiary or subsidiaries of
the Company now existing or formed after the date of this Agreement) shall
comply with the following covenants except as shall otherwise be expressly
agreed pursuant to a written consent or consents executed by Investors
holding not less than two-thirds of the shares of Convertible Preferred Stock
(or Common Stock, as applicable) held by the Investors as a group, until the
closing of a Qualified Public Offering (as defined in the Company's Articles
of Incorporation); provided, however, that the Company shall comply with the
covenant set forth in Sections 5.5, 5.10, 5.11, 5.12, 5.15, 5.16 and 5.19
below from and after the date hereof..

                  5.1      FINANCIAL STATIONS. The Company will maintain a
comparative system of accounts in accordance with generally accepted
accounting principles, keep full and complete financial records and furnish
to the Investors the following reports: (a) within 60 days after the end of
each fiscal year, a copy of the consolidated balance sheet of the Company as
at the end of such year, together with a consolidated statement of income and
retained earnings of the Company for such year, audited and certified by
independent public accountants of recognized national standing reasonably
satisfactory to the Investors, prepared in accordance with generally accepted
accounting principles and practices consistently applied; (b) within 45 days
after the end of each quarter commencing with the quarter ending December 31,
1997, a consolidated unaudited balance sheet of the Company as at the end of
such quarter and a consolidated unaudited statement of income and retained
earnings for the Company for such quarter and for the year to date; (c)
within 30 days after the end of each month commencing with the month ending
October 31, 1997 a consolidated unaudited balance sheet of the Company as at
the end of such month and an unaudited statement of income and retained
earnings for the Company for such month and for the year to date, each of the
foregoing balance sheets and statements of earnings and retained earnings to
set forth in comparative form the corresponding figures for the prior fiscal
period and to include a brief written discussion and analysis by management
of such annual, quarterly and monthly financial statements; and (d) such
other financial information as a two-thirds in interest of the Investors may
reasonably request, including without limitation certificates of the
principal financial officer of the Company concerning compliance with the
covenants of the Company under this Section 5.

                  5.2      BUDGET AND OPERATING FORECAST: INSPECTION. The
Company will prepare and submit to the Board of Directors of the Company a
budget for the Company for each fiscal year of the Company at least 30 days
prior to the beginning of such fiscal year, together with management's
written discussion and analysis of such budget. The budget shall be

                                       6
<PAGE>

accepted as the budget for such fiscal year when it has been approved by a
majority of the full Board of Directors of the Company and, thereupon, a copy
of such budget promptly shall be sent to the Investors. The Company shall
review the budget periodically and shall advise the Board of Directors and
the Investors of all changes therein and all material deviations therefrom.

         The Company will, upon reasonable prior notice to the Company,
permit authorized representatives of the Investors to visit and inspect any
of the properties of the Company and its subsidiaries, including its books of
account (and to make copies thereof and take extracts therefrom), and to
discuss its affairs, finances and accounts with its officers, administrative
employees and independent accountants, all at such reasonable times and as
often as may be reasonably requested.

                  5.3      BOARD MEETINGS; INDEMNIFICATION. The Company will
ensure that Meetings of its Board of Directors are held at least four times
each year. The Company will pay the nominees of the Investors who serve as
directors fees in an amount equal to any fees that are paid to other
non-management directors of the Company and will reimburse such Directors for
their reasonable travel expenses incurred in connection with attending
meetings of the Board of Directors and for their reasonable direct costs
associated with any other work on behalf of the Company.

                  5.4      CONDUCT OF BUSINESS. The Company will continue to
engage principally in the business now conducted by the Company or a business
or businesses similar thereto or reasonably compatible therewith. The Company
will keep in full force and effect its corporate existence and all
intellectual property rights useful in its business (except such rights as
the Board of Directors has reasonably determined are not material to the
Company's continuing operations).

                  5.5      HART-SCOTT-RODINO FILINGS. The Company shall
cooperate with the Investors in connection with all HSR Filings and shall
make all HSR Filings required in connection with the transactions
contemplated by this Agreement and shall furnish all follow-up information
required in connection therewith.

                  5.6      PAYMENT OF TAXES, COMPLIANCE WITH LAWS, ETC. The
Company will pay and discharge all lawful taxes, assessments and governmental
charges or levies imposed upon it or upon its income or property before the
same shall become in default, as well as all lawful claims for labor,
materials and supplies which, if not paid when due, might become a lien or
charge upon its property or any part thereof; provided, however, that the
Company shall not be required to pay and discharge any such tax, assessment,
charge, levy or claim so long as the validity thereof is being contested by
the Company in good faith by appropriate proceedings and an adequate reserve
therefor has been established on its books. The Company will comply with all
applicable laws and regulations in the conduct of its business, including,
without limitation, all applicable federal and state securities laws in
connection with the issuance of any shares of its capital stock.

                  5.7      INSURANCE. The Company will keep its insurable
properties insured, upon reasonable business terms, by financially sound and
reputable insurers against liability, and the perils of casualty, fire and
extended coverage in amounts of coverage at least equal to those

                                       7

<PAGE>

customarily maintained by companies in the same or similar business as the
Company. The Company will also maintain with such insurers insurance against
other hazards and risks and liability to persons and property to the extent
and in the manner customary for companies engaged in the same or similar
business.

                  5.8      KEY PERSON INSURANCE. The Company will use its
best efforts to maintain the coverage under the "key person" term life
insurance policy, if any, on the life of Ilhan Refioglu, provided such
insurance can be maintained at a commercially reasonable cost to the Company.
The Company hereby agrees that such policy shall not be assigned, borrowed
against or pledged.

                  5.9      MAINTENANCE OF PROPERTIES. The Company will
maintain all properties used or useful in the conduct of its business in good
repair, working order and condition, ordinary wear and tear excepted, as
necessary to permit such business to be properly and advantageously conducted.

                  5.10     MATERIAL ADVERSE CHANGES. The Company will
promptly advise the Investors of any event which represents or is reasonably
likely to result in a material adverse change in the condition (financial or
otherwise), business or prospects of the Company and its subsidiaries, and of
each suit or proceeding commenced or threatened against the Company or any of
its subsidiaries which, if adversely determined, in the reasonable judgment
of the Company, is reasonably likely to have a material adverse effect on the
Company and its subsidiaries or their condition (financial or otherwise),
business or prospects.

                  5.11     STOCK GRANTS. The Company and its subsidiaries
will not issue stock or grant stock options, warrants, other rights to
purchase stock or phantom stock rights in the Company or its subsidiaries to
their employees, officers, directors, consultants, advisers or independent
contractors except for the future issuance of up to 298,322 shares or options
on shares of Common Stock to employees of the Company and issuance of
incentive stock options to purchase up to 696,085 shares, in the aggregate,
of Common Stock promptly following the Closing to the certain employees of
the Company identified in SCHEDULE 5.11 attached hereto (in each case subject
to adjustments for stock splits, stock dividends and the like), pursuant to
and in accordance with the terms of the Company's 1997 Stock Option and Grant
Plan (the "Plan") as in effect on the Closing Date. Copies of the Plan and
the related forms of stock option/restricted stock agreements (including
vesting terms) are attached hereto as EXHIBIT I. Future options and
restricted stock may be granted to such employees, officers, directors,
consultants, advisors or independent contractors as the Compensation
Committee of the Company or the Board of Directors may determine, at prices
determined in good faith by the Compensation Committee or Board of Directors,
and otherwise on such terms as the Compensation Committee, or Board of
Directors shall determine. The Plan may not be amended, revised or waived
after the Closing Date without the consent of two-thirds in interest of the
Investors. Any grants of capital stock or options to a Key Executive shall be
conditioned-upon the grantee agreeing to be bound by the terms of the
Stockholders' Agreement with respect to the shares covered thereby.

                  5.12     AFFILIATED TRANSACTIONS. All transactions by and
between the Company and any of the Founder, or any other officer or key
employee of the Company or persons controlling, controlled by, under common
control with or otherwise affiliated with the

                                      8

<PAGE>

Founder or any officer or key employee, shall be conducted on an arm's-length
basis, shall be on terms and conditions no less favorable to the Company than
could be obtained from nonrelated persons and shall be approved in advance by
the Board of Directors after full disclosure of the terms thereof.

                  5.13     MANAGING UNDERWRITER. Selection of the managing or
lead underwriter for the Company's initial public offering shall be approved
by two-thirds-in-interest of the Investors, which approval shall not be
unreasonably withheld.

                  5.14     USE OF PROCEEDS. The Company will use the proceeds
from the sale of Preferred Shares and the funding of the Senior Indebtedness
under the Bank Financing as provided in SCHEDULE 5.14 hereto.

                  5.15     ENFORCEMENT OF RIGHTS. The Company will diligently
enforce all of its rights, including rights of indemnification, under the
Stock Redemption Agreement, the Employment Agreement referred to in Section
4.7 and the Confidentiality and Non-Competition Agreement referred to in
Section 4.8. The Company will not effect any transfer of any of the
outstanding capital stock of the Company on the stock record books of the
Company unless such transfer is made in accordance with the terms of the
Stockholders' Agreement. The Company will not waive or release any rights
under, consent to the amendment of, or modify, restate or terminate, any such
agreement without the written consent of two-thirds-in-interest of the
Investors.

                  5.16     DISTRIBUTIONS ON, AND REDEMPTIONS OF, CAPITAL
STOCK. Except as otherwise expressly provided in this Agreement, the
Redemption Agreement, the Option Cancellation Agreement or in the Articles of
Incorporation, the Company will not declare or pay any dividends or make any
distributions of cash, property or securities of the Company with respect to
any shares of its Common Stock or any other class of its capital stock, or
directly or indirectly redeem, purchase, or otherwise acquire for
consideration any shares of its Common Stock or any other class of its
capital stock; provided, however, that this restriction shall not apply to
the repurchase of (x) up to 390,000 shares of the Common Stock pursuant to
that certain Put Agreement, dated as of November __, 1997, by and among the
Company, the Founder and Golden Legacy, L.P. and (y) shares of Common Stock
pursuant to agreements under which the Company has the option or obligation
to repurchase such shares upon the occurrence of certain events, including
termination of employment, and a right of first refusal to acquire shares in
the event of certain proposed transfers. Any redemption, repurchase or other
acquisition by the Company of any shares of its capital stock shall be made
in compliance with all laws, including but not limited to federal and state
securities laws.

                  5.17     MERGER, CONSOLIDATION, SALE OF ASSETS,
ACQUISITIONS AND OTHER ACTIONS. The Company will not: (a) sell, lease or
otherwise dispose of (whether in one transaction or a series of related
transactions) all or substantially all of its assets, (b) merge with or into
or consolidate with another entity (except into or with a wholly-owned
subsidiary of the Company with the requisite shareholder approval), (c)
acquire any other corporation or business concern, whether by acquisition of
assets, capital stock or otherwise, and whether in consideration of the
payment of cash, the issuance of capital stock or otherwise, or make any
material investment in another business entity, (d) voluntarily liquidate or
wind up its operations,

                                       9

<PAGE>

(e) authorize the issuance of, issue or reserve for issuance, any equity
securities (including without limitation options, warrants, convertible or
exchangeable securities or rights giving the holder thereof the right to
acquire equity securities or any of the foregoing) or otherwise engage in any
equity financing, including without limitation in connection with a stock
acquisition, but excluding the issuance of stock options and/or restricted
stock as contemplated by Section 5.11, (f) create, or obligate itself to
create, any class or series of shares having preference over or being on a
parity with the Preferred Shares or the Redeemable Preferred Stock, (g)
create, incur, assume, become liable for, or-permit to exist any indebtedness
for borrowed money (other than the Senior Debt, as defined below), capital
leases, or other similar commitments or obligations, which, for any one such
borrowing or series of related borrowings, is in excess of $500,000, or (h)
enter into any agreement or arrangement or take any other action that
eliminates, amends, restricts or otherwise adversely affects the rights of
the holders of the Preferred Shares or the Company's ability to perform its
obligations hereunder or under the Amended and Restated Articles of
Incorporation or the Stockholders' Agreement; without limitation of the
foregoing, the Company shall take all action necessary or appropriate to
remove promptly any impediment to the redemption of the Preferred Shares or
the Redeemable Preferred Stock as contemplated by the Amended and Restated
Articles of Incorporation. For purposes of this Section 5.17, Senior Debt
shall mean indebtedness of the Company to any bank, trust company, insurance
company or other institutional lender providing financing to the Company.

                  5.18     NO AMENDMENTS TO ARTICLES OF INCORPORATION. Except
as contemplated by Section 5.21 below, the Company will not make any
amendment to Article IV of its Articles of Incorporation or make any other
amendment to its Articles of Incorporation or any amendment to its By-laws,
that eliminates, amends or restricts the rights and preferences of or
otherwise adversely affects the holders of the Preferred Stock or the
Redeemable Preferred Stock.

                  5.19     CAPITAL EXPENDITURES. The Company will not,
without the prior approval of the Board of Directors of the Company, make any
expenditures for fixed or capital assets, or any commitments for such
expenditures, exceeding an amount of $100,000 for any one such expenditure or
series of related expenditures.

                  5.20     REINCORPORATION. Promptly after the consummation
of the transactions contemplated by the Stock Redemption Agreement, the Bank
Financing Agreement and this Agreement, International Microcircuits, Inc., a
California corporation, shall consummate a re-incorporating merger with IMI
Acquisition Corporation, a Delaware corporation ("IMI Acquisition") pursuant
to which IMI Acquisition is the surviving corporation.

                  5.21     DISCLOSURE STATEMENT. The Company shall prepare
and distribute to all Optionholders a disclosure statement (the "Disclosure
Statement") setting forth all material information relating to the offer by
the Company to redeem all unexercised options held by the Optionholders as of
the Closing and relating to the transactions contemplated hereby and by the
Stock Redemption Agreement. The information contained in the Disclosure
Statement will not, from and after the date the Disclosure Statement (or any
amendment or supplement thereto) is first mailed to Optionholders until and
including the time of the Closing, contain any statement which, at such time
and in light of the circumstances under which it is made, is false or
misleading with respect to any material fact, or omits to state any material
fact required to be

                                      10

<PAGE>

stated therein or necessary in order to make the statements therein not false
or misleading or necessary to correct any statement in any earlier
communication with respect to the solicitation of the Optionholders with
respect to the transactions contemplated hereby and, by the Stock Redemption
Agreement which shall have become false or misleading. The Selling
Stockholders and the Investors shall cooperate with each other, and the
Selling Stockholders shall cause the Company to cooperate with the Investors,
in the preparation of the Disclosure Statement. The Company shall mail the
Disclosure Statement and all required amendments and supplements thereto to
the Optionholders at the earliest practicable time and in any event on or
prior to November __, 1997.

                  5.22     ADDITIONAL INFORMATION. The Company shall provide
the Investors with the opportunity to ask questions and receive answers
concerning the Company as well as the opportunity to obtain any additional
information necessary to verify the accuracy of information furnished in
connection with the transactions contemplated hereby which the Company
possesses or can acquire without unreasonable effort or expense.

         SECTION 6.          TERMINATION

                  6.1      This Agreement may be terminated at any time prior
to the Closing Date as follows:

                  (a)      by the mutual written consent of the Company and
two-thirds in interest of the Investors (the "Majority Investors");

                  (b)      by either the Company or the Majority Investors if
the Stock Redemption Agreement has been terminated;

                  (c)      by either the Company or the Majority Investors if
the Closing has not occurred on or before the day which is ten (10) business
days after the latest to occur of (i) the date on which the Secretary of
State of the State of California shall have approved of the Company's Amended
and Restated Articles, of Incorporation and such Amended and Restated
Articles of Incorporation shall have become effective, (ii) the date on which
all conditions to the closing of the transactions contemplated by that
certain Loan Agreement by and between the Company and Fleet National Bank, as
agent and a lender, and certain other financial institutions named therein
shall have been satisfied and (iii)(x) each Optionholder shall have received
an Option Cancellation Agreement and the related Disclosure Statement, (y)
the period for the acceptance of the offer set forth in the Option
Cancellation Agreement shall have expired and (z) the condition to closing
set forth in Sections 4.l(b) and 4.l(c) hereof shall have been satisfied;
provided, however, that neither party may terminate this Agreement pursuant
to this clause (c) if the Closing has not occurred as a result of the failure
of such party to perform in all material respects all of its obligations
hereunder.

         SECTION 7.          GENERAL

                  7.1      AMENDMENTS WAIVERS AND CONSENTS. For the purposes of
this Agreement and all agreements executed pursuant hereto, no course of dealing
between or among any of the parties hereto and no delay on the part of any party
hereto in exercising any rights hereunder or thereunder shall operate as a
waiver of the rights hereof and thereof. No provision

                                      11

<PAGE>

hereof may be waived otherwise than by a written instrument signed by the
parties so waiving such covenant or other provision; provided, however, in
the case of the Investors, changes in or additions to, and any consents or
waivers given pursuant to, this Agreement may be made, and compliance with
any term, covenant, condition or provision set forth herein may be omitted or
waived (either generally or in a particular instance and either retroactively
or prospectively) by a consent of the Investors in accordance with Section
7.2. Any amendment or waiver effected in accordance with this Section 7.1
shall be binding upon each holder of Preferred Shares or Conversion Shares at
the time outstanding, each future holder of all such securities and the
Company and each of their assigns.

                  7.2      ACTIONS OR CONSENTS OF INVESTORS. Any actions
required to be taken or consents, approvals, votes or waivers required or
contemplated to be given by the Investors shall require a vote of
two-thirds-in-interest of the Investors based on their relative holdings of
Preferred Shares or Conversion Shares at the relevant time.

                  7.3      INDEMNIFICATION FROM THE COMPANY: EXPENSES.

                  (a)      Without limitation of any other provision of this
Agreement, the Company agrees to defend, indemnify and hold the Investors and
their affiliates and their respective direct and indirect partners, members,
Stockholders, directors, officers, employees and agents and each person who
controls any of them within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act of 1934, as amended (the "Exchange Act")
(parties receiving the benefit of the indemnification agreement herein shall
be referred to collectively as "Indemnified Parties" and individually as an
"Indemnified Party") harmless from and against any and all losses, claims,
damages, obligations, liens, assessments, judgments, fines, liabilities, and
other costs and expenses (including without limitation interest, penalties
and any investigation, reasonable, legal and accountant fees and other
expenses incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted, as the same are
incurred) of any kind or nature whatsoever which may be sustained or suffered
by any such Indemnified Party, without regard to any investigation by any of
the Indemnified Parties, based upon, arising out of, by reason of or
otherwise in respect of or in connection with (i) any breach of any covenant
or agreement made by the Company in this Agreement or in any agreement or
instrument delivered pursuant to or in connection with this Agreement, or of
(ii) their status as a securityholder, creditor, director, agent,
representative or controlling person of the Company (including, without
limitation, any and all Losses under the Securities Act, the Exchange Act or
other federal or state statutory law or regulation, at common law or
otherwise, which relates directly or indirectly to the registration,
purchase, sale or ownership of any securities of the Company or to any
fiduciary obligation owed with respect thereto), including without limitation
in connection with any third party or governmental action or claim relating
to any action taken or omitted to be taken or alleged to have been taken or
omitted to have been taken by any Indemnified Party as shareholder, director,
agent, representative or controlling person of the Company or otherwise,
alleging so-called control person liability or securities law liability;
provided, however, that the Company will not be liable to the extent that
such loss, claim, damage, expense or liability arises from and is based on
(A) an untrue statement or omission or alleged untrue statement or omission
in a registration statement or prospectus which is made in reliance on and in
conformity with written information furnished to the Company in an instrument
duly executed by or on behalf of such Indemnified Party specifically stating
that it

                                      12

<PAGE>

is for use in the preparation thereof or (B) a knowing and willful violation
of the federal securities laws by an Indemnified Party, as finally determined
by a court of competent jurisdiction.

                  (b)      If the indemnification provided for in Section
7.3(a) above for any reason is held by a court of competent jurisdiction to
be unavailable to an Indemnified Party in respect of any losses, claims,
damages, expenses or liabilities referred to therein, then the Company, in
lieu of indemnifying such Indemnified Party thereunder, shall contribute to
the amount paid or payable by such Indemnified Party as a result of such
losses, claims, damages, expenses or liabilities (i) in such proportion as is
appropriate to reflect the relative benefits received by the Company and the
Investors, or (ii) if the allocation provided by clause (i) above is not
permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause (i) above but also the
relative fault of the Company and the Investors in connection with the action
or inaction which resulted in such losses, claims, damages, expenses or
liabilities, as well as any other relevant equitable considerations. In
connection with any registration of the Company's securities, the relative
benefits received by the Company and the Investors shall be deemed to be in
the same respective proportions that the net proceeds from the offering
(before deducting expenses) received by the Company and the Investors, in
each case as set forth in the table on the cover page of the applicable
prospectus, bear to the aggregate public offering price of the securities so
offered. The relative fault of the Company and the Investors shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company or the
Investors and the parties' relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission.

         The Company and the Investors agree that it would not be just and
equitable if contribution pursuant to this Section 7.3(b) were determined by
pro rata or per capita allocation or by any other method of allocation which
does not take account of the equitable considerations referred to in the
immediately preceding paragraph. In connection with the registration of the
Company's securities, in no event shall an Investor be required to contribute
any amount under this Section 7.3(b) in excess of the lesser of (i) that
proportion of the total of such losses, claims, damages or liabilities
indemnified against equal to the proportion of the total securities sold
under such registration statement which is being sold by such Investor or
(ii) the proceeds received by such Investor from its sale of securities under
such registration statement. No person found guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not found guilty of
such fraudulent misrepresentation.

                  (c)      The indemnification and contribution provided for
in this Section 6.3 will remain in full force and effect regardless of any
investigation made by or on behalf of the Indemnified Parties or any officer,
director, partner, employee, agent or controlling person of the Indemnified
Parties.

                  (d)      The provisions of this Section 7.3 are in addition
to and shall supplement those set forth in the Stockholders' Agreement which
shall apply in the case of the

                                      13
<PAGE>

registration and sale of Registrable Securities held by any of the Investors
registered as provided in the Stockholders' Agreement.

                  (e)      The Company agrees to pay and hold the Investors
harmless against liability for payment of all reasonable out-of-pocket costs
and expenses incurred in connection with their ongoing investment in the
Company, including without limitation the fees and disbursements of counsel
and other professionals and any costs and expenses associated with the
performance and enforcement of this Agreement and the agreements, documents
and instruments contemplated hereby or executed pursuant hereto. In addition,
the Company agrees to pay any and all stamp, transfer and other similar taxes
(together in each case with interest and penalties, if any) payable or
determined to be payable in connection with the execution and delivery of
this Agreement and the issuance of securities hereunder.

                  7.4      SURVIVAL OF REPRESENTATIONS; ASSIGNABILITY OF
RIGHTS; NO THIRD PARTY BENEFICIARIES. All representations, warranties,
covenants and agreements of the Company made herein and in the certificates,
exhibits and schedules delivered to any Investor in connection herewith (a)
are material and shall be deemed to have been relied upon by such Investor,
and shall survive the delivery of the Securities and (b) shall bind the
Company's successors and assigns, whether so expressed or not, and, except as
otherwise provided in this Agreement, all such covenants, agreements,
representations and warranties shall inure to the benefit of the Investors'
successors and assigns and to transferees of the Securities, whether so
expressed or not, with any such assignee (and any successive assignee
thereof) being deemed an "Investor" for purposes hereof. Nothing in this
Agreement, express or implied, is intended to confer upon any person other
than the parties hereto or their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this
Agreement.

                  7.5      GOVERNING LAW. This Agreement shall be deemed to
be a contract made under, and shall be construed in accordance with, the laws
of California, without giving effect to conflict of laws principles thereof.

                  7.6      SECTION HEADINGS AND GENDER. The descriptive
headings in this Agreement have been inserted for convenience only and shall
not be deemed to limit or otherwise affect the construction of any provision
thereof or hereof. The use in this Agreement of the masculine pronoun in
reference to a party hereto shall be deemed to include the feminine or
neuter, and vice versa, as the context may require.

                  7.7      COUNTERPARTS. This Agreement may be executed
simultaneously in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall
together constitute but one and the same document.

                  7.8      NOTICES AND DEMANDS. Any notice or demand which is
required or provided to be given under this Agreement shall be deemed to have
been sufficiently given and received for all purposes when delivered by hand,
telecopy, telex or other method of facsimile, or five (5) days after being
sent by certified or registered mail, postage and charges prepaid, return
receipt requested, or two (2) days after being sent by overnight delivery
providing receipt of delivery, to the addresses shown on the signature page
hereof or on EXHIBIT A hereto or at any

                                      14

<PAGE>

other address designated by such Investor to the Company; and if to an
assignee of an Investor, at its address as designated to the Company and the
other Investors in writing.

                  7.9      DISPUTE RESOLUTION. Except with respect to matters
as to which injunctive relief is being sought, any dispute arising out of or
relating to this Agreement that has not been settled within thirty (30) days
by good faith negotiation between the parties to this Agreement shall be
submitted for final and binding arbitration pursuant to the commercial
arbitration rules of the American Arbitration Association. Any such
arbitration shall be conducted in San Francisco, California.

                  7.10     REMEDIES; SEVERABILITY. Notwithstanding Section
7.9, it is specifically understood and agreed that any breach of the
provisions of this Agreement by any person subject hereto will result in
irreparable injury to the other parties hereto, that the remedy at law alone
will be an inadequate remedy for such breach, and that, in addition to any
other legal or equitable remedies which they may have, such other parties may
enforce their respective rights by actions for specific performance (to the
extent permitted by law). Whenever possible, each provision of this Agreement
shall be interpreted in such a manner as to be effective and valid under
applicable law, but if any provision of this Agreement shall be deemed
prohibited or invalid under such applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, and such
prohibition or invalidity shall not invalidate the remainder of such
provision or the other provisions of this Agreement.

                  7.11     INTEGRATION. This Agreement, including the
exhibits, documents and instruments referred to herein or therein,
constitutes the entire agreement, and supersedes all other prior agreements
and understandings, both written and oral, among the parties with respect to
the subject matter hereof.

                  [Remainder of Page Intentionally Left Blank]

                                      15

<PAGE>

         IN WITNESS WHEREOF, the undersigned have executed this Agreement as
a sealed instrument as of the day and year first above written.

                                     INTERNATIONAL MICROCIRCUITS, INC.

                                     By:
                                        --------------------------------------
                                     Name:
                                     Title:

                                     Address:  525 Los Coches Street
                                               Milpitas, CA 95035
                                               Fax: (408) 934-0823
                                               Attention:  President

<PAGE>

                                     INVESTORS:

                                     TA/ADVENT VIII, L P.
                                     By:      TA Associates VIII, LLC,
                                              its General Partner
                                     By:      TA Associates, Inc.,
                                              its Manager

                                     -----------------------------------------
                                     Name:
                                     Title:  Managing Director

                                     ADVENT ATLANTIC AND PACIFIC III L.P.
                                     By:      TA Associates AAP III Partners,
                                              its General Partner
                                     By:      TA Associates, Inc.,
                                              its General Partner

                                     -----------------------------------------
                                     Name:
                                     Title:  Managing Director

                                     TA INVESTORS LLC
                                     By:      TA Associates, Inc.,
                                              its Manager

                                     -----------------------------------------
                                     Name:
                                     Title:  Managing Director

--------------------------------
By:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]